Christian G. Hartinger (born 1974) is an Austrian-born New Zealand

bioinorganic Bioinorganic chemistry is a field that examines the role of metals in biology. Bioinorganic chemistry includes the study of both natural phenomena such as the behavior of metalloproteins as well as artificially introduced metals, including those t ...

chemist known for his work in metal-based anticancer drugs. In 2022 he was elected a Fellow of the Royal Society Te Apārangi.

Scientific career

Hartinger studied chemistry at the University of Vienna, earning his MSc in 1999 and his PhD in 2001 under Bernhard Keppler. He was an Erwin Schrödinger Fellow with Paul Dyson at the École Polytechnique Fédérale de Lausanne from 2006 to 2008 and obtained his

habilitation Habilitation is the highest university degree, or the procedure by which it is achieved, in many European countries. The candidate fulfills a university's set criteria of excellence in research, teaching and further education, usually including a ...

at the University of Vienna in 2009. In 2011, Hartinger was appointed the position of

associate professor Associate professor is an academic title with two principal meanings: in the North American system and that of the ''Commonwealth system''. Overview In the ''North American system'', used in the United States and many other countries, it is a ...

at Waipapa Taumata Rau, where he currently serves and in 2015 was promoted to professor. Hartinger's research interests are in bioinorganic chemistry, medicinal chemistry, and

bioanalytical chemistry Bioanalysis is a sub-discipline of analytical chemistry covering the quantitative measurement of xenobiotics (drugs and their metabolites, and biological molecules in unnatural locations or concentrations) and biotics (macromolecules, proteins, ...

, where he uses an interdisciplinary approach in

drug discovery In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by ...

. He is specially interested in the development of metal-centred anticancer agents, particularly ruthenium anticancer drugs, and using analytical methods to characterise their behaviour in the presence of biomolecules. Hartinger has now published over 169 publications and has an h-index of 69. In 2022 Hartinger was elected a Fellow of the Royal Society Te Apārangi. The society said his "innovative approaches have established new directions in metallodrug research, and his developed methodologies continue to have far-reaching impact in the community. His findings challenge paradigms about the reactivity of metal compounds towards biomolecules and thereby inform the design of novel biomaterials".

Distinctions/honours

Selected research outputs

* Meier, S. M.; Novak, M. S.; Kandioller, W.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G., Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. ''Dalton Trans'', 2014, ''43'' (26), 9851–9855 * Meier, S. M.; Babak, M. V.; Keppler, B. K.; Hartinger, C. G., Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. ''ChemMedChem'', 2014, ''9'' (7), 1351–1355 * Hartinger, C. G.; Groessl, M.; Meier, S. M.; Casini, A.; Dyson, P. J., Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. ''Chem Soc Rev'', 2013, ''42'' (14), 6186–6199 * Meier, S. M.; Novak, M.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Metzler-Nolte, N.; Keppler, B. K.; Hartinger, C. G., Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. ''Chem Eur J'', 2013, ''19'' (28), 9297–9307 * Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Göschl S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G., Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. ''Chem Commun'', 2013, ''49'' (32), 3348–3350 * Meier, S. M.; Hanif, M.; Pichler, V.; Novak, M.; Jirkovsky, E.; Jakupec, M. A.; Davey, C. A.; Keppler, B. K.; Hartinger, C. G., Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents. ''Chem Sci'', 2013, ''4'' (4), 1837–1846 * Babak, M. V.; Meier, S. M.; Legin, A. A.; Adib Razavi, M. S.; Roller, A.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G., Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. ''Chemistry'', 2013, 19 (13), 4308–4318 *Kurzwernhart, A.; Kandioller, W.; Bächler S.; Bartel, C.; Martic, S.; Buczkowska, M.; Mühlgassner, G.; Jakupec, M. A.; Kraatz, H.; Berdnarski, P. J.; Arion, V. B.; Markos, D.; Keppler, B. K.; Hartinger, C. G., Structure-activity relationships of targeted Ru^II(η⁶-''p''-cymene) anticancer complexes with flavonol-derived ligands. ''J Med Chem'', 2012, 55 (23), 10512-10522

References

External links

Hartinger group WebpageUniversity of Auckland staff profileArticles on Google Scholar
{{DEFAULTSORT:Hartinger, Christian 21st-century chemists Inorganic chemists Analytical chemists New Zealand chemists Academic staff of the University of Auckland University of Vienna alumni 1974 births Living people Scientists from Vienna Fellows of the Royal Society of New Zealand